Skip to main content
INVEX THERAPEUTICS LTD logo

INVEX THERAPEUTICS LTD — Investor Relations & Filings

Ticker · IXC ISIN · AU0000048621 ASX Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country AU Australia
Listing ASX IXC

About INVEX THERAPEUTICS LTD

https://invextherapeutics.com

Invex Therapeutics Ltd focuses on the development and commercialization of treatments for neurological conditions associated with raised intracranial pressure. The company’s primary clinical program involves repurposing exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, specifically for Idiopathic Intracranial Hypertension (IIH). Its lead candidate, Presendin™, is a proprietary formulation of exenatide designed to inhibit cerebrospinal fluid production at the choroid plexus, effectively lowering intracranial pressure. Invex addresses a significant unmet medical need, as there are currently no regulatory-approved pharmacological treatments for IIH. The company is progressing its lead candidate through the IIH EVOLVE Phase III clinical trial, targeting improvements in headache disability and visual outcomes for patients suffering from this chronic condition.

Recent filings

Filing Released Lang Actions
Invex to Expand Preclinical Research Program 2 pages 191.4KB
Regulatory Filings Classification · 75% confidence The document is an ASX media release announcing the expansion of a preclinical research program. It is not an earnings release, financial report, AGM material, or any specific transaction notice. It is a general corporate update filed under continuous disclosure obligations, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-23 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 669.6KB
Interim / Quarterly Report Classification · 100% confidence The document is an 'Appendix 4C' quarterly cash flow report combined with a quarterly activities report for Invex Therapeutics. In the Australian market (ASX), Appendix 4C filings are standard quarterly financial disclosures for entities not primarily engaged in mining or oil and gas exploration. Since it contains substantive financial data (cash flow statements) and operational analysis for a specific fiscal quarter, it falls under the definition of an Interim/Quarterly Report (IR). Q3 2026
2026-04-23 English
Resignation of Joint Company Secretary 1 page 134.5
Board/Management Information Classification · 100% confidence The document is a media release announcing the resignation of a Joint Company Secretary, referencing compliance with ASX Listing Rule 3.16.1. It is a corporate governance-related announcement about a change in senior management personnel. There is no financial data, no report attached or referenced, and the document is short (1078 characters). This fits the category of Board/Management Information (MANG).
2026-03-22 English
Results of Meeting 2 pages 156.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX media release dated 17 February 2026 announcing the results of the Annual General Meeting (AGM) of Invex Therapeutics Limited. It includes detailed proxy and poll voting results for resolutions passed at the AGM, such as adoption of the remuneration report and election/re-election of directors. The content focuses on the official voting outcomes from the shareholder meeting, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2833 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM presentation or annual report. There is no detailed financial data or management discussion, so it is not an Annual Report or Management Report. Therefore, the correct classification is DVA with high confidence.
2026-02-16 English
Appendix 4D and Half Year Report 19 pages 1.1MB
Interim / Quarterly Report Classification · 98% confidence The document is titled 'APPENDIX 4D – HALF-YEAR FINANCIAL REPORT' and covers the half year ended 31 December 2025, with detailed financial statements, directors' report, auditor's review report, and notes to the financial statements. It includes comprehensive financial data, operational highlights, corporate information, and auditor's independence declaration. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the correct classification is IR with high confidence.
2026-02-11 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 982.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'December Quarterly Activities Report & Appendix 4C' and is dated 22 January 2026. It provides an operational and corporate update for the quarter ended 31 December 2025 (Q2 FY26). The document includes detailed cash flow statements (Appendix 4C), operational updates, corporate updates including board changes, and financial summary and analysis for the quarter. The presence of the Appendix 4C cash flow report, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly report. The document is comprehensive, contains substantive financial data and analysis for a period shorter than a full fiscal year, and is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-01-21 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.